Evidence map›Paper›PMID 25564714›Full record

ArticleCell cycle (Georgetown, Tex.)2015

In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by taxol.

V G Minero, D De Stefanis, P Costelli, F M Baccino, G Bonelli

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.Journal of experimental & clinical cancer research : CR · 2016
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

V G Mineroa Department of Clinical and Biological Sciences ; Experimental Medicine and Clinical Pathology Unit; University of Turin ; Turin , Italy.
D De Stefanis
P Costelli
F M Baccino
G Bonelli
University of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High mortality among hepatocellular carcinoma (HCC) patients reflects both late diagnosis and low curability, due to pharmacoresistance. Taxol (TAX) is toxic for many human HCC-derived cell lines, yet its clinical efficacy on HCCs is poor. Combining TAX with other drugs appears a promising possibility to overcome such refractoriness. We analyzed whether combining tumor necrosis factor (TNF) with TAX would improve their toxicity. Human HCC-derived cell lines were treated with TAX or TNF, alone or combined. Apoptosis was assessed by morphology and flow-cytometry. Several pro- and anti-apoptotic molecules were evaluated by western blotting and/or enzymatic assay. After a 24 hour treatment, TNF was ineffective and TAX modestly cytotoxic, whereas HCC cells were conditionally sensitized to TNF by TAX. Indeed some relevant parameters were shifted to a prodeath setting: TNF-receptor 1 was increased, SOCS3, c-FLIP and pSTAT3 were markedly downregulated. These observations provide a significant clue to critically improve the drug susceptibility of HCC cells by combining 2 agents, TAX and TNF. The sequential application of TAX at a low dosage followed by TNF for only a short time triggered a strong apoptotic response. Of interest, prior TAX administration could also sensitize to TNF-induced apoptosis in the Yoshida AH-130 hepatoma transplanted in mice. Therefore, scrutinizing the possibility to develop similar combination drug regimens in suitable preclinical models seems highly advisable.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicCarcinoma, HepatocellularCASP8 and FADD-Like Apoptosis Regulating ProteinCaspasesCell ShapeCell SurvivalDrug Resistance, NeoplasmDrug Screening Assays, AntitumorEnzyme ActivationHep G2 CellsHumansLiver NeoplasmsMaleMice, Inbred BALB CNeoplasm TransplantationAntineoplastic Agents, PhytogenicCASP8 and FADD-Like Apoptosis Regulating ProteinCaspasesCFLAR protein, humanPaclitaxelReceptors, Tumor Necrosis Factor, Type ISOCS3 protein, humanSTAT3 protein, humanSTAT3 Transcription FactorSuppressor of Cytokine Signaling 3 ProteinSuppressor of Cytokine Signaling ProteinsTNF protein, humanTumor Necrosis Factor-alphaapoptosisCOL, colchicineDAPI, 4,6-diamidino-2-phenylindole dihydrochlorideHCC, hepatocellular carcinomahepatocellular carcinomaNOC, nocodazoleSOCS3SOCS3, suppressor of cytokine signaling 3STAT3, signal transducer and activator of tanscription 3TAXTAX, taxol (paclitaxel)TNFTNF-R1, TNF-receptor 1TNF, tumor necrosis factor-αTRAIL, tumor necrosis factor-related apoptosis-inducing ligand

Identifiers

PMID25564714
PMCPMC4614628
OpenAlexW1875639257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.